Professor Charles Pusey
Professor of Medicine and Head of Section, Renal Section, Imperial College, London.

Updated July 2023 – Dr Steven McAdoo Consultant Nephrologist and Research Fellow, Imperial College London 

What is anti-GBM disease?

Anti-glomerular basement membrane (GBM) disease, also known as Goodpasture’s disease, is a rare condition that causes inflammation of the small blood vessels in the kidneys and lungs.

Who are affected?

This disease tends to affect two age groups – young people aged 20 to 30, and older people in their 60s and 70s. Men are affected slightly more often than women.

What is the aetiology (cause)?

The disease occurs when the body’s immune system attacks the lining (known as the basement membrane) of the small blood vessels in the kidneys and lungs. It is not currently known why this occurs, although people with a particular “tissue type” seem to be at greater risk. Lung involvement is more common in cigarette smokers, and it is thought smoking may also be a trigger for developing the disease.

What are the symptoms?

Anti-GBM disease usually develops suddenly, over a period of a few weeks. The kidneys, the lungs, or both may be affected. Most individuals with anti-GBM disease have kidney involvement, and about 50 per cent of patients have lung disease in addition to kidney disease. Isolated lung disease is very rare. Kidney involvement may not cause symptoms at first, although blood and protein may be detected in the urine. As the disease progresses, patients may develop signs of kidney failure such as tiredness, poor appetite, decreased urine production, breathlessness and leg swelling. When the lungs are involved, patients may have severe breathless, dry cough, or coughing up blood.

Making a diagnosis

The diagnosis of anti-GBM disease usually relies on a blood test to identify anti-GBM antibodies. Often a kidney biopsy (taking a small sample of kidney tissue with a needle) is required to demonstrate that the kidneys are involved. This may also confirm the diagnosis, by showing deposition of anti-GBM antibodies in the kidney. Other tests (such as X-rays or CT scans) are often used to show if the lungs are involved. It is important to make a diagnosis of anti-GBM rapidly, as treatment is more likely to be effective when started early in the disease course.


Treatment requires a process called plasma exchange, which involves the use of a machine to remove anti-GBM antibodies from the bloodstream. This is often done daily for 2 weeks. In addition, immunosuppressive drugs such as steroids and cyclophosphamide, are used to suppress inflammation and stop further antibody production. Rituximab is sometimes used as an additional or alternative immunosuppressive treatment to cyclophosphamide. Treatment usually continues for 6 months after the diagnosis is made.

For information on plasma exchange:

Drugs and Side Effects

For information on the main drugs prescribed for Anti-GBM (Goodpasture’s) disease see:

For information on other drugs used in the treatment of vasculitis see Glossary of drugs and side effects.


When treatment is started promptly, before the need for kidney dialysis, the majority of patients recover to have normal kidney and lung function. However, patients already on dialysis are unlikely to recover kidney function. Unlike some other forms of vasculitis, it is very rare for anti-GBM disease to relapse, and thus it does not usually require long-term treatment. Smoking is thought to be a possible trigger for causing relapses, and should be avoided. In patients remaining on dialysis, kidney transplantation is possible once anti-GBM antibodies have become undetectable and recurrence of the disease is a transplanted kidney is very rare.

Anti-GBM disease ANCA-associated vasculitis

It is recognised that some patients with anti-GBM disease are also found to have ANCA, which are antibodies usually associated with other forms of small vessel vasculitis such as Granulomatosis with Polyangiitis and Microscopic Polyangiitis (see individual diseases for more information). We believe these “double positive” patients should receive initial treatment as for anti-GBM disease, including plasma exchange, at the time of diagnosis. Despite having both types of antibodies, the response to this treatment is similar to patients with anti-GBM disease alone. However, unlike patients with isolated anti-GBM disease, they are at risk of future relapses related to their ANCA, and so we recommend that they continue on longer-term maintenance treatment (like those patients with isolated ANCA-related disease.)

Novel treatments

Imlifidase, a protein derived from bacteria than can rapidly digest the antibodies that cause kidney and lung damage, has shown promise as a novel treatment option for anti-GBM disease. Imlifidase is currently being tested in an international trial of patients with anti-GBM disease, which includes some hospitals in the UK. Until the results of this trial are known, it is not yet available as a routine treatment.

Key points

  • Anti-GBM disease is a rare form of vasculitis
  • It causes damage to small blood vessels in the kidneys and lungs
  • Diagnosis is confirmed by detecting anti-GBM antibodies in blood or deposited in the kidney
  • Treatment with plasma exchange (to remove anti-GBM antibodies) together with prednisolone and cyclophosphamide is usually successful
  • Patients with “double positive’ ANCA and anti-GBM disease require longer term treatment than those with anti-GBM disease alone.

Further reading

Personal story

The personal story of a young man with Anti GBM (Goodpasture’s Disease) can be viewed at: Gareth’s Story